Edgestream Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-13,806
| Closed | -$3.25M | – | 826 |
|
|
2024
Q4 | $3.25M | Buy |
+13,806
| New | +$3.25M | 0.14% | 291 |
|
|
2024
Q3 | – | Sell |
-6,052
| Closed | -$1.47M | – | 824 |
|
|
2024
Q2 | $1.47M | Sell |
6,052
-17,303
| -74% | -$4.2M | 0.07% | 426 |
|
|
2024
Q1 | $3.49M | Buy |
23,355
+15,394
| +193% | +$2.3M | 0.17% | 198 |
|
|
2023
Q4 | $1.52M | Buy |
7,961
+5,536
| +228% | +$1.06M | 0.11% | 309 |
|
|
2023
Q3 | $429K | Sell |
2,425
-9,120
| -79% | -$1.62M | 0.03% | 628 |
|
|
2023
Q2 | $2.19M | Buy |
11,545
+3,872
| +50% | +$735K | 0.2% | 159 |
|
|
2023
Q1 | $1.54M | Buy |
+7,673
| New | +$1.54M | 0.17% | 197 |
|
|
2022
Q3 | – | Sell |
-10,785
| Closed | -$1.57M | – | 443 |
|
|
2022
Q2 | $1.57M | Buy |
10,785
+6,783
| +169% | +$989K | 0.12% | 248 |
|
|
2022
Q1 | $653K | Sell |
4,002
-17,985
| -82% | -$2.93M | 0.05% | 383 |
|
|
2021
Q4 | $3.73M | Buy |
21,987
+5,566
| +34% | +$944K | 0.23% | 136 |
|
|
2021
Q3 | $3.1M | Buy |
16,421
+4,740
| +41% | +$895K | 0.19% | 182 |
|
|
2021
Q2 | $1.98M | Buy |
+11,681
| New | +$1.98M | 0.12% | 221 |
|